SciBase Secures Full Coverage for SEK 57.5M Rights Issue
Event summary
- Bergs Securities AB confirmed a SEK 24.2M guarantee commitment, covering 42% of SciBase's SEK 57.5M rights issue.
- Existing shareholders and management have committed SEK 33.3M in subscription undertakings, covering the remaining 58%.
- The rights issue, priced at SEK 15 per share, runs from September 15 to September 29, 2026.
- Subscription rights traded on Nasdaq First North Growth Market until September 24, 2026.
- Outcome of the rights issue expected to be announced on or around October 1, 2026.
The big picture
SciBase's successful securing of full coverage for its rights issue underscores strong investor backing amid a push for early detection solutions in dermatology. The SEK 57.5M raise comes as medical technology firms increasingly rely on targeted capital raises to fund AI-driven diagnostic advancements. The involvement of a consortium of investors highlights strategic alignment with SciBase's mission to minimize patient suffering through proactive skin health management.
What we're watching
- Capital Deployment
- How SciBase will allocate the SEK 57.5M proceeds to accelerate Nevisense commercialization and R&D.
- Investor Confidence
- Whether the full coverage of the rights issue signals sustained investor confidence in SciBase's growth trajectory.
- Market Positioning
- The pace at which SciBase can leverage this funding to strengthen its competitive position in dermatology diagnostics.
